Scarica l'app Stockscreener
28.54
1.89%
-0.55
Dopo l'orario di chiusura:
28.43
-0.11
-0.39%
Precedente Chiudi:
$29.09
Aprire:
$29.06
Volume 24 ore:
116.33K
Relative Volume:
0.80
Capitalizzazione di mercato:
$961.72M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+4.54%
1M Prestazione:
+7.13%
6M Prestazione:
+30.32%
1 anno Prestazione:
+32.44%
Intervallo 1D:
$28.34
$29.71
Intervallo di 1 settimana:
$26.79
$29.71
Portata 52W:
$14.35
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Nome
Arrivent Biopharma Inc
Settore
Industria
Telefono
240-780-6356
Indirizzo
18 CAMPUS BLVD., NEWTOWN SQUARE
Confronta AVBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
28.54 | 961.72M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-22 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-20 | Iniziato | Citigroup | Buy |
| 2024-02-20 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | Jefferies | Buy |
Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Bought by JPMorgan Chase & Co. - Defense World
(AVBP) Trading Signals - Stock Traders Daily
ArriVent in Newtown Square Sees Big Potential in New Cancer Drug - DELCO.Today
Abbvie seeks molecular glue degraders from Neomorph - BioCentury
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN
Equities Analysts Set Expectations for AVBP Q1 Earnings - Defense World
HC Wainwright Issues Positive Estimate for AVBP Earnings - MarketBeat
More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal - BioWorld Online
ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright - Yahoo Finance
ArriVent Biopharma enters license agreement with Lepu Biopharma - MSN
Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim - MedCity News
Intellia makes progress on HAE study; 2 more China drug deals - BioPharma Dive
ArriVent inks ADC licensing deal with Lepu Biopharma - The Pharma Letter
ArriVent bets big on experimental cancer drug with potential $1B licensing deal - The Business Journals
Arrivent Biopharma licenses ex-China rights to Lepu’s ADC for gastrointestinal cancers - BioWorld Online
ArriVent Joins Chinese Licensing Trend With Potential $1.2B+ ADC Deal with Lepu - BioSpace
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the - Digital More
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers - The Manila Times
Lepu Biopharma Co., Ltd. Enters into an Exclusive Licensing Agreement with Arrivent Biopharma, Inc - Marketscreener.com
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma - WICZ
Lepu Biopharma Grants Exclusive License for Novel ADC MRG007 to ArriVent - TipRanks
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers - The Manila Times
ArriVent BioPharma Secures Global Rights to Promising Cancer Drug MRG007 in $1.2B Deal - StockTitan
(AVBP) Investment Analysis - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 13.1% in December - MarketBeat
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap DownWhat's Next? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Barclays PLC Has $976,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Jane Street Group LLC Has $250,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate - Simply Wall St
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 5%Should You Sell? - MarketBeat
Geode Capital Management LLC Increases Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Barclays PLC Increases Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stock Position Increased by Geode Capital Management LLC - MarketBeat
Barclays PLC Buys 38,132 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
(AVBP) Proactive Strategies - Stock Traders Daily
State Street Corp Acquires 323,186 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stake Lifted by State Street Corp - Defense World
(AVBP) Pivots Trading Plans and Risk Controls - Stock Traders Daily
The Manufacturers Life Insurance Company Purchases Shares of 10,234 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 6.1% in November - MarketBeat
Charles Schwab Investment Management Inc. Buys 122,641 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
BNP Paribas Financial Markets Raises Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Purchases 169,514 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
Suvretta Capital Management, LLC Acquires Additional Shares in A - GuruFocus.com
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Decreases By 11.9% - MarketBeat
Suvretta Capital Management LLC Purchases 132,459 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
Arrivent Biopharma Inc Azioni (AVBP) Dati Finanziari
Non sono disponibili dati finanziari per Arrivent Biopharma Inc (AVBP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):